BRIEF published on 04/25/2025 at 15:44, 11 months 1 day ago Pentixapharm to Showcase Innovative Antibody GT-008 at AACR 2025 Cancer Therapy Pentixapharm GT-008 Antibody Glycan-Dependent CD24 Targeting
PRESS RELEASE published on 04/25/2025 at 15:39, 11 months 1 day ago Pentixapharm to Present First-in-Class Glycan-Dependent CD24 Antibody GT-008 for Solid Tumors at AACR 2025 Pentixapharm to present novel CD24 antibody GT-008 for solid tumors at AACR 2025, showcasing glycan-dependent mechanism for targeted therapy Solid Tumors Pentixapharm AACR 2025 GT-008 CD24 Antibody
BRIEF published on 04/24/2025 at 14:05, 11 months 2 days ago Pentixapharm signe un accord de fabrication pour la thérapie à l'yttrium-90 Eckert & Ziegler Essais Cliniques Produits Radiopharmaceutiques Pentixapharm Yttrium-90
BRIEF published on 04/24/2025 at 14:05, 11 months 2 days ago Pentixapharm Signs Manufacturing Deal for Yttrium-90 Therapy Clinical Trials Eckert & Ziegler Radiopharmaceuticals Pentixapharm Yttrium-90
PRESS RELEASE published on 04/24/2025 at 14:00, 11 months 2 days ago Pentixapharm Signs Contract Manufacturing Agreement for Yttrium-90-based PentixaTher with Eckert & Ziegler SE Pentixapharm signs manufacturing agreement for Yttrium-90-based PentixaTher with Eckert & Ziegler SE to produce CXCR4-targeting radiotherapeutic doses for clinical trials Clinical Trials Eckert & Ziegler SE Pentixapharm Y90-PentixaTher Radiotherapeutic
BRIEF published on 04/15/2025 at 08:22, 11 months 11 days ago Pentixapharm Holding AG publie ses résultats financiers pour 2024 et ses perspectives pour 2025 Recherche Et Développement Résultats Financiers 2024 Prévisions Financières 2025 Innovation Radiopharmaceutique Stratégie Pentixapharm
BRIEF published on 04/15/2025 at 08:22, 11 months 11 days ago Pentixapharm Holding AG Reports 2024 Financial Results and 2025 Outlook Research And Development Financial Results 2024 2025 Financial Forecast Radiopharmaceutical Innovation Pentixapharm Strategy
PRESS RELEASE published on 04/15/2025 at 08:17, 11 months 11 days ago Pentixapharm Holding AG Releases Financial Results for 2024 and Announces Guidance for the 2025 Financial Year Pentixapharm Holding AG releases 2024 financial results with EUR 12.8 million net loss and guides for EUR 23.5 million loss in 2025, focusing on R&D and operating expenses Financial Results 2024 Net Loss 2025 Pentixapharm
BRIEF published on 03/03/2025 at 14:43, 1 year ago Pentixapharm Holding AG Announces Board Changes Supervisory Board Board Changes Leadership Transition Pentixapharm Governance Dr. Andreas Eckert
BRIEF published on 03/03/2025 at 14:43, 1 year ago Pentixapharm Holding AG annonce des changements au sein de son conseil d'administration Conseil De Surveillance Transition De Direction Changements Au Sein Du Conseil D'administration Dr. Andreas Eckert Gouvernance De Pentixapharm
Published on 03/26/2026 at 16:20, 3 hours 29 minutes ago ACCESS Newswire Upgrades the ACCESS Platform to Include Social Monitoring to Track Brand Conversations Across Major Social Platforms
Published on 03/26/2026 at 13:00, 6 hours 49 minutes ago Prospect Ridge Strengthens Technical Team with Appointment of Phil Smerchanski as Senior Technical Advisor
Published on 03/26/2026 at 13:00, 6 hours 49 minutes ago GameSquare's Stream Hatchet Launches Creator Communities to Manage the Full Creator Marketing Lifecycle
Published on 03/26/2026 at 12:59, 6 hours 50 minutes ago Adcore Concludes Fiscal Year 2025 With Strong Q4 Performance
Published on 03/26/2026 at 19:20, 28 minutes ago Critical Path Institute Launches 'One to Millions' to Reshape the Future of Individualized Medicine at Global Scale
Published on 03/26/2026 at 19:09, 39 minutes ago 2CRSi SA: Résultats 1er Semestre 2025/26 : Chiffre d'Affaires 204,7 M€ (x9,8) EBITDA de 9,6 M€ (x4,6)
Published on 03/26/2026 at 19:09, 39 minutes ago 2CRSi SA: First Half 2025/26 Results: Revenue of €204.7 million (x9.8) EBITDA of €9.6 million (x4.6)
Published on 03/26/2026 at 18:17, 1 hour 32 minutes ago Eiffage se renforce au capital de Getlink et porte sa participation à 29,40 % du capital
Published on 03/26/2026 at 18:17, 1 hour 32 minutes ago Eiffage strengthens its position in Getlink capital
Published on 03/26/2026 at 18:00, 1 hour 49 minutes ago Arrêté des comptes au 31 décembre 2025 et perspectives 2026
Published on 03/26/2026 at 18:00, 1 hour 49 minutes ago LABORATOIRES EUROMEDIS - Fin du contrat de liquidité
